Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Liabilities (2016 - 2025)

Lipocine's Total Liabilities history spans 14 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 22.13% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, up 22.13%, while the annual FY2024 figure was $1.5 million, 42.51% down from the prior year.
  • Total Liabilities reached $1.9 million in Q3 2025 per LPCN's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $11.4 million in Q2 2021 to a low of $1.3 million in Q1 2025.
  • Average Total Liabilities over 5 years is $3.4 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: tumbled 79.85% in 2022, then skyrocketed 37.93% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $6.9 million in 2021, then tumbled by 72.4% to $1.9 million in 2022, then skyrocketed by 37.93% to $2.6 million in 2023, then plummeted by 42.51% to $1.5 million in 2024, then grew by 27.64% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Total Liabilities are $1.9 million (Q3 2025), $1.4 million (Q2 2025), and $1.3 million (Q1 2025).